Calliditas Therapeutics-ADRCALT
13F holders, Q2 2024 (June 30)18holders −1
5new positions
6sold out
$39.09avg. 13F price*
At the end of Q2 2024, 18 institutions reported holding Calliditas Therapeutics-ADR (CALT) in their 13F filings, down 1 from Q1 2024. 5 opened new positions and 6 sold out. The largest holders were BVF Inc. ($29.2M), Ironwood Investment Management LLC ($999K) and Optiver Holding B.V. ($871K).
- Company
- Calliditas Therapeutics-ADR
- CUSIP
- 13124Q106
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $764K |
| Exits | 6 | $1.5M |
All 13F filers, Q1 2024 → Q2 2024: 37,351 shares bought and 83,407 shares sold, net −46,056 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| BVF Inc. | 0.82% | No change | 750,000 | $29.2M |
| Ironwood Investment Management LLC | 0.53% | Add +0.5% | 25,627 | $999K |
| Optiver Holding B.V. | 0.02% | Add +781.5% | 22,336 | $871K |
| UBS Group AG | 0.00% | New | 10,756 | $419K |
| PenderFund Capital Management Ltd. | 0.19% | New | 6,000 | $320K |
| Susquehanna International Group, LLP | 0.00% | Reduce -47.5% | 5,397 | $210K |
| Wells Fargo & Company | 0.00% | Reduce -60.1% | 1,500 | $58K |
| Morgan Stanley | 0.00% | Reduce -84.7% | 919 | $36K |
| Planning Capital Management Corp | 0.02% | No change | 877 | $34K |
| Bank of America Corp. | 0.00% | Reduce -37.0% | 656 | $26K |
| Global Retirement Partners, LLC | 0.00% | New | 500 | $19K |
| Osaic Holdings, Inc. | 0.00% | Reduce -76.9% | 255 | $10K |
| Rhumbline Advisers | 0.00% | Add +23.2% | 202 | $8K |
| EverSource Wealth Advisors, LLC | 0.00% | New | 125 | $5K |
| Colonial Trust Advisors | 0.00% | No change | 105 | $4K |
| Missouri Trust & Investment Co | 0.00% | No change | 35 | $1K |
| Qube Research & Technologies Ltd | 0.00% | Reduce -76.4% | 17 | $663 |
| CIBC Private Wealth Group LLC | 0.00% | New | 14 | $546 |
"% of holder's portfolio" is CALT's weight in each manager's 13F, not the share of Calliditas Therapeutics-ADR the manager owns.